Position
Squarepoint Ops LLC in Nektar Therapeutics
Back to the book · All holders of NKTR
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $601K$42.28 → $71.95
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 20.3K | $856.5K | — | — | — | 0.0% |
| Q1 2026 | 107.4K | $7.73M | $71.95 | $601K | $6.27M | 0.0% |